The analyst's decision to maintain a Buy rating suggests continued confidence in Fennec Pharmaceuticals' prospects, which is positive. However, the lowered price target from $15 to $13 indicates a tempered outlook, potentially due to revised expectations or market conditions. This mixed signal may result in a neutral short-term impact on the stock price.